Logo

Celgene and Acceleron Report FDA's Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia

Share this

Celgene and Acceleron Report FDA's Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia

Shots:

  • The BLA acceptance follows safety and efficacy data from two P-III MEDALIST and BELIEVE study result assessing Luspatercept vs PBO to treat anemia associated with MDS and beta-thalassemia- with its results presented at ASH 2018  
  • The US FDA has also granted Priority Review to Luspatercept’s BLA for Beta-Thalassemia with PDUFA date of Dec 4-2019 and Apr 4-2020 for Myelodysplastic Syndromes
  • Luspatercept is a novel erythroid maturation agent (EMA) regulating late-stage red blood cell maturation currently evaluated in P-III COMMANDS study for ESA-naïve- lower-risk MDS patients. Additionally- Luspatercept’s MAA is validated in EU with its ongoing review

Ref: Celgene | Image: Behance

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions